Summary

Semax is a synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10). It is classified as a nootropic and neuroprotective agent, distinguished by its ability to modulate brain-derived neurotrophic factor (BDNF) and expression of nerve growth factors. It is studied for its cognitive-enhancing properties, neuroprotection during ischemia, and immune modulation. For research use only—not for human consumption.

Clinical Data

Research in rodent models demonstrates that Semax rapidly elevates BDNF levels in the hippocampus and basal forebrain, which is associated with improved neuronal survival and synaptic plasticity. In models of ischemic stroke, animals treated with Semax exhibited significantly reduced infarct volume and improved neurological scoring compared to controls. Additionally, studies on cognitive function indicate that the peptide enhances selective attention and memory consolidation. The peptide has shown a favorable safety profile in animal studies, with no hormonal activity related to the full ACTH molecule.